Spire (US) launches Spi-Polymer surface treatment:
This article was originally published in Clinica
Executive Summary
Spire (US) has developed the Spi-Polymer process which reduces biofouling on the surface of polymeric components of IVD assay devices. The surface treatment is applied to devices using ion implantation technology, providing a more hydrophilic surface which reduces blood cell, air bubble and plasma protein adherence. The reduction of biofouling improves accuracy for diagnostic assay systems by enhancing flow performance and reducing maintenance, says Spire.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.